EDUCATIONAL DESIGN OVERVIEW
A debilitating, chronic disorder mediated by the irreversible loss of hypocretin/orexin (ORX) neurons, narcolepsy type 1 (NT1) is often misdiagnosed or underdiagnosed. Moreover, while there are a number of available therapies for NT1, many are associated with adverse effects and are symptomatic. However, novel agents that target the pathophysiology of NT1 have demonstrated efficacy and safety profiles in recent studies. [break] [break] Join our expert faculty for this virtual [italic]Care Team Forum℠[/italic] symposium, featuring a series of panel discussions on recognition, pathophysiology, and treatment of NT1. Each panel topic will be augmented by the perspectives of an experienced patient with NT1, who will share valuable teaching moments from their therapeutic journey.
GOAL STATEMENT
This CE activity was designed to improve learners' knowledge and competence in relation to the management of patients with NT1.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to: [LIST] [ITEM]Recognize contemporary challenges in the management of NT1 [ITEM]Evaluate the role of orexin in the underlying pathophysiology of NT1 [ITEM]Analyze available data on emerging orexin-based therapies for the treatment of NT1 [ITEM]Identify patients with NT1 who might derive benefit from treatment with orexin-based therapy [/LIST]
ACCREDITATION STATEMENT
[JALOGO] In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians [/bold] RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 [italic]AMA PRA Category 1 Credit(s)™[/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.
Supported by an educational grant from [bold] Takeda Development Center Americas, Inc.[/bold]
Provided by RMEI Medical Education, LLC.